Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATYR NASDAQ:IRD NASDAQ:OVID NASDAQ:SNDL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATYRaTyr Pharma$0.56+41.4%$0.82$0.40▼$7.29$38.82M0.662.25 million shs13.84 million shsIRDOpus Genetics$4.97-1.2%$4.99$0.90▼$5.81$409.42M0.62964,353 shs905,466 shsOVIDOvid Therapeutics$2.80$2.48$0.27▼$3.11$369.25M0.182.16 million shs1.32 million shsSNDLSNDL$1.46+3.5%$1.43$1.15▼$2.89$362.93M0.883.05 million shs2.20 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATYRaTyr Pharma+41.42%-39.26%-33.42%-37.36%-81.52%IRDOpus Genetics-1.19%-7.28%-10.45%+36.54%+423.16%OVIDOvid Therapeutics0.00%+2.56%-5.41%+97.18%+849.47%SNDLSNDL+3.55%+0.69%+1.39%-2.67%+14.06%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATYRaTyr Pharma$0.56+41.4%$0.82$0.40▼$7.29$38.82M0.662.25 million shs13.84 million shsIRDOpus Genetics$4.97-1.2%$4.99$0.90▼$5.81$409.42M0.62964,353 shs905,466 shsOVIDOvid Therapeutics$2.80$2.48$0.27▼$3.11$369.25M0.182.16 million shs1.32 million shsSNDLSNDL$1.46+3.5%$1.43$1.15▼$2.89$362.93M0.883.05 million shs2.20 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATYRaTyr Pharma+41.42%-39.26%-33.42%-37.36%-81.52%IRDOpus Genetics-1.19%-7.28%-10.45%+36.54%+423.16%OVIDOvid Therapeutics0.00%+2.56%-5.41%+97.18%+849.47%SNDLSNDL+3.55%+0.69%+1.39%-2.67%+14.06%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATYRaTyr Pharma 2.00Hold$25.674,484.15% UpsideIRDOpus Genetics 2.79Moderate Buy$10.20105.23% UpsideOVIDOvid Therapeutics 2.89Moderate Buy$5.1383.04% UpsideSNDLSNDL 1.67Reduce$5.00242.47% UpsideCurrent Analyst Ratings BreakdownLatest ATYR, SNDL, OVID, and IRD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2026OVIDOvid Therapeutics Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.005/13/2026IRDOpus Genetics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$12.00 ➝ $11.005/12/2026IRDOpus Genetics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/30/2026IRDOpus Genetics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy4/29/2026SNDLSNDL Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/28/2026IRDOpus Genetics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform4/28/2026IRDOpus Genetics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Perform$12.004/21/2026IRDOpus Genetics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026OVIDOvid Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/15/2026OVIDOvid Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$7.004/9/2026OVIDOvid Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$2.00 ➝ $4.00(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATYRaTyr Pharma$190K288.94N/AN/A$0.69 per share0.81IRDOpus Genetics$14.20M28.49N/AN/A($0.56) per share-8.88OVIDOvid Therapeutics$7.25M50.93N/AN/A$1.50 per share1.87SNDLSNDL$937.39M0.40$0.12 per share12.52$3.08 per share0.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATYRaTyr Pharma-$74.12M-$0.79N/AN/AN/AN/A-99.87%-74.41%N/AIRDOpus Genetics-$49.59M-$1.33N/AN/AN/A-892.36%-709.20%-191.21%5/21/2026 (Estimated)OVIDOvid Therapeutics-$17.41M-$0.29N/AN/AN/A-240.11%-22.51%-18.67%N/ASNDLSNDL-$11.29M-$0.03N/A36.50N/A-1.19%-1.02%-0.85%7/30/2026 (Estimated)Latest ATYR, SNDL, OVID, and IRD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026IRDOpus Genetics-$0.16N/AN/AN/A$3.14 millionN/A5/12/2026Q1 2026IRDOpus Genetics-$0.16-$0.75-$0.59-$0.75$2.93 million$2.16 million5/12/2026Q1 2026OVIDOvid Therapeutics-$0.12-$0.12N/A-$0.12$0.06 millionN/A3/18/2026Q4 2025OVIDOvid Therapeutics-$0.10$0.06+$0.16$0.06$0.06 million$0.72 million3/12/2026Q4 2025SNDLSNDL$0.01$0.0291+$0.0191$0.03$257.97 million$183.87 million3/5/2026Q4 2025ATYRaTyr Pharma-$0.18-$0.14+$0.04-$0.14$0.02 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATYRaTyr PharmaN/AN/AN/AN/AN/AIRDOpus GeneticsN/AN/AN/AN/AN/AOVIDOvid TherapeuticsN/AN/AN/AN/AN/ASNDLSNDLN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATYRaTyr PharmaN/A5.305.30IRDOpus GeneticsN/A7.136.43OVIDOvid Therapeutics0.0610.178.97SNDLSNDL0.124.843.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATYRaTyr Pharma61.72%IRDOpus Genetics14.97%OVIDOvid Therapeutics72.24%SNDLSNDLN/AInsider OwnershipCompanyInsider OwnershipATYRaTyr Pharma5.75%IRDOpus Genetics11.70%OVIDOvid Therapeutics13.10%SNDLSNDLN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATYRaTyr Pharma5398.05 million92.41 millionOptionableIRDOpus Genetics1481.40 million63.05 millionN/AOVIDOvid Therapeutics60131.88 million114.60 millionOptionableSNDLSNDL2,751257.40 millionN/AOptionableATYR, SNDL, OVID, and IRD HeadlinesRecent News About These CompaniesAlliance Global Partners Keeps Their Buy Rating on SNDL (SNDL)May 6, 2026 | theglobeandmail.comATB Cormark Capital Markets Keeps Their Buy Rating on SNDL (SNDL)May 6, 2026 | theglobeandmail.comShould SNDL Stock Be in Your Portfolio Post Q1 Earnings?May 6, 2026 | finance.yahoo.comShould SNDL Stock Be in Your Portfolio Post Q1 Earnings?May 6, 2026 | zacks.comSNDL Inc. (SNDL) Reports its First-quarter 2026 ResultsMay 1, 2026 | finance.yahoo.comSNDL Inc. (SNDL) Reports its First-quarter 2026 ResultsMay 1, 2026 | insidermonkey.comSNDL (NASDAQ:SNDL) Rating Lowered to "Strong Sell" at Zacks ResearchMay 1, 2026 | marketbeat.comSNDL Inc. Q1 2026 Earnings Call SummaryApril 30, 2026 | finance.yahoo.comSNDL Quarterly Revenue Dented By Soft Liquor, Cannabis Market ConditionsApril 30, 2026 | marketwatch.comSNDL sends pot stocks lower as market headwinds drive Q1 revenue missApril 30, 2026 | msn.comForget SNDL: HITI is a Significantly Better Cannabis StockApril 30, 2026 | 247wallst.comForget SNDL: HITI is a Significantly Better Cannabis StockApril 30, 2026 | 247wallst.comSNDL Inc. Disappoints With Declining Q1 2026 RevenueApril 30, 2026 | seekingalpha.comSNDL Inc. Earnings Call: Cost Cuts Amid Cannabis StrainApril 29, 2026 | tipranks.comSNDL Inc. (SNDL) Q1 2026 Earnings Call TranscriptApril 29, 2026 | seekingalpha.comSNDL Q1 Earnings Call HighlightsApril 29, 2026 | marketbeat.comSNDL (SNDL) Q1 2026 Earnings TranscriptApril 29, 2026 | fool.comSNDL Inc. Q1 2026 Earnings Call SummaryApril 29, 2026 | app.moby.coASNDL Reports First Quarter 2026 Financial and Operational ResultsApril 29, 2026 | finance.yahoo.comSNDL Reports First Quarter 2026 Financial and Operational ResultsApril 29, 2026 | globenewswire.comSNDL Inc. (NASDAQ:SNDL) Short Interest Up 39.5% in AprilApril 28, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Space ETFs to Pick Up Before SpaceX IPOBy Nathan Reiff | April 19, 2026The New Nokia: A Bullish Upgrade Ignites This Big AI Bet By Jeffrey Neal Johnson | April 16, 2026Is Oracle Undervalued as Cloud Growth Accelerates?By Thomas Hughes | April 29, 2026Is Backblaze the Next Momentum Monster?By Jeffrey Neal Johnson | May 7, 2026Forget The Chips? Cloud Stocks Are The New Hardware By Jeffrey Neal Johnson | April 17, 2026ATYR, SNDL, OVID, and IRD Company DescriptionsaTyr Pharma NASDAQ:ATYR$0.56 +0.16 (+41.42%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$0.56 +0.01 (+0.91%) As of 06:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.Opus Genetics NASDAQ:IRD$4.97 -0.06 (-1.19%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$5.04 +0.07 (+1.31%) As of 05:55 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.Ovid Therapeutics NASDAQ:OVID$2.80 0.00 (0.00%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$2.76 -0.03 (-1.25%) As of 05/14/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.SNDL NASDAQ:SNDL$1.46 +0.05 (+3.55%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$1.42 -0.04 (-2.74%) As of 06:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
